People born with a certain gene change that breaks the PCSK9 gene tend to have much lower 'bad' cholesterol their whole lives and are far less likely to get heart disease — so scientists think blocking this gene with medicine might help protect others' hearts too.
See the scientific wording
Loss-of-function mutations in the PCSK9 gene are associated with lifelong lower low-density lipoprotein (LDL) cholesterol levels and an 88% reduced risk of coronary artery disease, indicating that pharmacological inhibition of PCSK9 may confer cardiovascular protection by reducing LDL receptor degradation and increasing clearance of LDL cholesterol from the bloodstream.
Correlational — new studies may shift this
One low-scoring study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Narrative ReviewReview2020
The study looks at drugs that block a protein called PCSK9, which helps lower bad cholesterol and reduces heart disease risk, just like what happens in people with natural mutations in the PCSK9 gene. This supports the idea that blocking PCSK9 is protective for the heart.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
People born with a certain gene change that breaks the PCSK9 gene tend to have much lower 'bad' cholesterol their whole lives and are far less likely to get heart disease — so scientists think blocking this gene with medicine might help protect others' hearts too.
Evidence from Studies
Supporting (1)
Community contributions welcome
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
The study looks at drugs that block a protein called PCSK9, which helps lower bad cholesterol and reduces heart disease risk, just like what happens in people with natural mutations in the PCSK9 gene. This supports the idea that blocking PCSK9 is protective for the heart.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of PCSK9 Inhibitors on LDL Cholesterol and Coronary Artery Disease Outcomes in High-Risk Populations
Systematic review of randomized controlled trials evaluating PCSK9 inhibitors (e.g., evolocumab, alirocumab) vs placebo in adults with elevated cardiovascular risk, measuring changes in LDL-C and incidence of coronary artery disease over ≥2 years.
Double-Blind Placebo-Controlled Trial of PCSK9 Inhibitor Therapy on LDL Receptor Activity and Cardiovascular Events
Randomized, double-blind, placebo-controlled trial in 10,000 participants with hypercholesterolemia, treated with a PCSK9 inhibitor vs placebo for 5 years, tracking LDL-C levels, LDL receptor expression, and incidence of myocardial infarction or revascularization.
Longitudinal Study of Individuals with PCSK9 Loss-of-Function Mutations and Cardiovascular Outcomes
Prospective cohort study following carriers of PCSK9 loss-of-function mutations and non-carriers over 30 years, measuring LDL-C trajectories and coronary artery disease incidence from early adulthood.
Case-Control Study of PCSK9 Mutation Frequency in Patients with Early-Onset Coronary Artery Disease vs Healthy Controls
Matched case-control study comparing prevalence of PCSK9 loss-of-function variants in 1,000 patients with early-onset coronary artery disease versus 1,000 age- and sex-matched controls without disease.
In Vitro Analysis of PCSK9 Inhibition on LDL Receptor Degradation in Human Hepatocytes
Laboratory study using cultured human liver cells to assess how silencing or inhibiting PCSK9 affects LDL receptor protein levels and LDL particle uptake over 72 hours.